Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development

Stem cells possess the dual properties of self‐renewal and pluripotency. Self‐renewal affords these populations the luxury of self‐propagation, whereas pluripotency allows them to produce the multitude of cell types found in the body. Protection of the stem cell population from damage or death is critical because these cells need to remain intact throughout the life of an organism. The principal mechanism of protection is through expression of multifunctional efflux transporters—the adenosine triphosphate–binding cassette (ABC) transporters that are the “guardians” of the stem cell population. Ironically, it has been shown that these ABC efflux pumps also afford protection to cancer stem cells (CSCs), shielding them from the adverse effects of chemotherapeutic insult. It is therefore imperative to gain a better understanding of the mechanisms involved in the resistance of stem cells to chemotherapy, which could lead to the discovery of new therapeutic targets and improvement of current anticancer strategies.

[1]  M. Mimeault,et al.  Recent Progress on Tissue-Resident Adult Stem Cell Biology and Their Therapeutic Implications , 2008, Stem Cell Reviews.

[2]  J. Sandrini,et al.  Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. , 2010, Leukemia research.

[3]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[4]  Heshui Wu,et al.  Persistence of side population cells with high drug efflux capacity in pancreatic cancer. , 2008, World journal of gastroenterology.

[5]  D. Sullivan,et al.  Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. , 2006, Cancer research.

[6]  Liang Xu,et al.  MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications , 2009, The AAPS Journal.

[7]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[8]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[9]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Niederwieser,et al.  ABCG2 expression is correlated neither to side population nor to hematopoietic progenitor function in human umbilical cord blood. , 2009, Experimental hematology.

[11]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[12]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[13]  T. Gallardo,et al.  Hypoxia-Inducible Factor-2&agr; Transactivates Abcg2 and Promotes Cytoprotection in Cardiac Side Population Cells , 2008, Circulation research.

[14]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[15]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[16]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[17]  E. Barta,et al.  Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. , 2006, The Journal of biological chemistry.

[18]  C. Gilissen,et al.  Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells , 2010, BMC pharmacology.

[19]  Suneet Shukla,et al.  Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter , 2007, Molecular Cancer Therapeutics.

[20]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[21]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[22]  M. Dean,et al.  Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. , 2007, Journal of medicinal chemistry.

[23]  K. Scotto,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001, Molecular interventions.

[24]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[25]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[26]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.

[27]  W. Jin,et al.  Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. , 2007, Biochemical pharmacology.

[28]  M. Cornwell.  The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  D. Clarke,et al.  Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. , 1994, The Journal of biological chemistry.

[30]  M. Cornwell,et al.  SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. , 1993, The Journal of biological chemistry.

[31]  F. Baas,et al.  Identification of a functional initiator sequence in the human MDR1 promoter. , 1993, Biochimica et Biophysica Acta.

[32]  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. , 2008, Current molecular pharmacology.

[33]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[34]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[35]  K. Scotto,et al.  Differential Regulation of MDR1 Transcription by the p53 Family Members , 2005, Journal of Biological Chemistry.

[36]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[37]  M. Raaijmakers,et al.  ABCB1 Modulation Does Not Circumvent Drug Extrusion from Primitive Leukemic Progenitor Cells and May Preferentially Target Residual Normal Cells in Acute Myelogenous Leukemia , 2006, Clinical Cancer Research.

[38]  M. Shackleton.  Normal stem cells and cancer stem cells: similar and different. , 2010, Seminars in cancer biology.

[39]  P. Leung,et al.  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.

[40]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[41]  M. Sayegh,et al.  Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter* , 2003, Journal of Biological Chemistry.

[42]  Johnson Ra,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001 .

[43]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[44]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[45]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[46]  M. Herlyn,et al.  Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population , 2010, Oncogene.

[47]  A. Whitehead,et al.  The 3′ Untranslated Region of the Membrane-Bound IL-1R Accessory Protein mRNA Confers Tissue-Specific Destabilization , 2004, The Journal of Immunology.

[48]  Scott E. Martin,et al.  Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. , 2006, Cancer research.

[49]  H. Lehrach,et al.  Cancer stem cells in solid tumors: elusive or illusive? , 2010, Cell Communication and Signaling.

[50]  I. Weissman,et al.  A Genetic Determinant That Specifically Regulates the Frequency of Hematopoietic Stem Cells1 , 2002, The Journal of Immunology.

[51]  B. Ogretmen,et al.  Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. , 1999, Biochemistry.